Jie Min Luo
Vorstandsvorsitzender bei AMOY DIAGNOSTICS CO., LTD.
Aktive Positionen von Jie Min Luo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AMOY DIAGNOSTICS CO., LTD. | Direktor/Vorstandsmitglied | 13.08.2021 | - |
| Vorstandsvorsitzender | 01.12.2021 | - | |
| Investor Relations Kontakt | 18.06.2015 | - | |
| Unternehmenssekretär | 18.06.2015 | 01.12.2021 | |
SinoPath Medical Investment (Beijing) Co., Ltd.
 SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Jie Min Luo
Statistik
International
| China | 3 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Investor Relations Contact | 1 |
Sektoral
| Health Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMOY DIAGNOSTICS CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
SinoPath Medical Investment (Beijing) Co., Ltd.
SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Health Services |
- Börse
- Insiders
- Jie Min Luo
- Erfahrung
